Literature DB >> 23078371

Effect of pH, temperature, and salt on the stability of Escherichia coli- and Chinese hamster ovary cell-derived IgG1 Fc.

Cynthia H Li1, Linda O Narhi, Jie Wen, Mariana Dimitrova, Zai-qing Wen, Jenny Li, Joseph Pollastrini, Xichdao Nguyen, Trace Tsuruda, Yijia Jiang.   

Abstract

The circulation half-life of a potential therapeutic can be increased by fusing the molecule of interest (an active peptide, the extracellular domain of a receptor, an enzyme, etc.) to the Fc fragment of a monoclonal antibody. For the fusion protein to be a successful therapeutic, it must be stable to process and long-term storage conditions, as well as to physiological conditions. The stability of the Fc used is critical for obtaining a successful therapeutic protein. The effects of pH, temperature, and salt on the stabilities of Escherichia coli- and Chinese hamster ovary cell (CHO)-derived IgG1 Fc high-order structure were probed using a variety of biophysical techniques. Fc molecules derived from both E. coli and CHO were compared. The IgG1 Fc molecules from both sources (glycosylated and aglycosylated) are folded at neutral pH and behave similarly upon heat- and low pH-induced unfolding. The unfolding of both IgG1 Fc molecules occurs via a multistep unfolding process, with the tertiary structure and C(H)2 domain unfolding first, followed by changes in the secondary structure and C(H)3 domain. The acid-induced unfolding of IgG1 Fc molecules is only partially reversible, with the formation of high-molecular weight species. The CHO-derived Fc protein (glycosylated) is more compact (smaller hydrodynamic radius) than the E. coli-derived protein (aglycosylated) at neutral pH. Unfolding is dependent on pH and salt concentration. The glycosylated C(H)2 domain melts at a temperature 4-5 °C higher than that of the aglycosylated domain, and the low-pH-induced unfolding of the glycosylated Fc molecule occurs at a pH ~0.5 pH unit lower than that of the aglycosylated protein. The difference observed between E. coli- and CHO-derived Fc molecules primarily involves the C(H)2 domain, where the glycosylation of the Fc resides.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23078371     DOI: 10.1021/bi300702e

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab.

Authors:  Fabienne Courtois; Neeraj J Agrawal; Timothy M Lauer; Bernhardt L Trout
Journal:  MAbs       Date:  2016       Impact factor: 5.857

2.  Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.

Authors:  Thomas Spreter Von Kreudenstein; Eric Escobar-Carbrera; Paula I Lario; Igor D'Angelo; Karine Brault; John Kelly; Yves Durocher; Jason Baardsnes; R Jeremy Woods; Michael Hongwei Xie; Pierre-Alain Girod; Michael D L Suits; Martin J Boulanger; David K Y Poon; Gordon Y K Ng; Surjit B Dixit
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

3.  Construction strategies for developing expression vectors for recombinant monoclonal antibody production in CHO cells.

Authors:  Yan-Mei Li; Zheng-Wei Tian; Dan-Hua Xu; Xiao-Yin Wang; Tian-Yun Wang
Journal:  Mol Biol Rep       Date:  2018-09-06       Impact factor: 2.316

4.  High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.

Authors:  Mohammad A Alsenaidy; Jae Hyun Kim; Ranajoy Majumdar; David D Weis; Sangeeta B Joshi; Thomas J Tolbert; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-09-24       Impact factor: 3.534

5.  Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis.

Authors:  Solomon Z Okbazghi; Apurva S More; Derek R White; Shaofeng Duan; Ishan S Shah; Sangeeta B Joshi; C Russell Middaugh; David B Volkin; Thomas J Tolbert
Journal:  J Pharm Sci       Date:  2016-01-09       Impact factor: 3.534

6.  Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro.

Authors:  Ling Liu; Frederick W Jacobsen; Nancy Everds; Yao Zhuang; Yan Bin Yu; Nianyu Li; Darcey Clark; Mai Phuong Nguyen; Madeline Fort; Padma Narayanan; Kei Kim; Riki Stevenson; Linda Narhi; Kannan Gunasekaran; Jeanine L Bussiere
Journal:  J Biol Chem       Date:  2016-12-19       Impact factor: 5.157

7.  Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297.

Authors:  Mohammad A Alsenaidy; Solomon Z Okbazghi; Jae Hyun Kim; Sangeeta B Joshi; C Russell Middaugh; Thomas J Tolbert; David B Volkin
Journal:  J Pharm Sci       Date:  2014-04-16       Impact factor: 3.534

8.  Comparison of microbial and transient expression (tobacco plants and plant-cell packs) for the production and purification of the anticancer mistletoe lectin viscumin.

Authors:  Benjamin B Gengenbach; Linda L Keil; Patrick Opdensteinen; Catherine R Müschen; Georg Melmer; Hans Lentzen; Jens Bührmann; Johannes F Buyel
Journal:  Biotechnol Bioeng       Date:  2019-06-29       Impact factor: 4.530

9.  High-throughput thermal stability analysis of a monoclonal antibody by attenuated total reflection FT-IR spectroscopic imaging.

Authors:  Maxime Boulet-Audet; Bernadette Byrne; Sergei G Kazarian
Journal:  Anal Chem       Date:  2014-09-26       Impact factor: 6.986

Review 10.  Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.

Authors:  Chunpeng Yang; Xinyu Gao; Rui Gong
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.